View
1.851
Download
0
Category
Preview:
Citation preview
RecentTrendsandChangesinR&D/BDamongKorean
biopharmasJamesJungkueLee
BridgeBiotherapeutics,Inc
BioKorea 2016
1
Opening
• Koreabiopharma industryhasundergoneprofoundchangesin2015/6season,30yearsafterKoreagovernmentamendedpatentlawtoimplementCOM(compositionofmatter)patentin1987.Hanmi’s stringsofsuperdealsin2015hasraisedthelevelofself-confidenceacrossKoreabiopharma industryandhasmadeex-Koreabiopharma industryplayersconsiderKoreaemergingandprovensourceofinnovations.Insuchinternalandexternalchanges,pharmas andbiotechs hascautiouslyintroducedchangesintoitsR&DandBDstrategy.Thispresentationwilltrytorecapsuchchangesinlast12monthsandsuggestseveralrecommendationstoKoreanandex-Koreanbiopharma.
2
BridgeBiotherapeutics,Inc.
• Virtuallyoperatingbiotech• Anoveltargetbiologywithpotentialformultiple
indications• IND-enablingGLPstudywillbeinitiatedinH2,2016
3
KoreanBiopharma industry-Genesisü1988• Adoptionof”COM”patent• NCEdiscovery(mostlyme-tooapproach)started
ü1997• Firstwaveoflicensing-outtobigpharma• LGLifeSciences,Yuhan,SKCorp
4
KoreanBiopharma industry-Genesis
5
KoreanBiopharma industry-Genesis
6
KoreanBiopharma industry-Growthü1999/2000• >200biotechstartups• Traditionalpharmas startedNCE/NMEresearch
ü2015• Hanmi Pharma’sserialhome-rundeals
7
KoreanBiopharma industry-Growth
8
KoreanBiopharma industry- Now
üVCindustryisgettingsmarter.• Moreexperiencedventurecapitals• Fundsizehasincreased
üAcademiacontinuestobringnovelsciences• Maturescience• Professor/academicresearchersstartedtorespectindustry
üIndustry• Hungerfornoveltyduetocontinuedfailurewith“me-too”approach
9
KoreanBiopharma industry- NowandNearFuture
10
CurrentTrends
üBiotechsectorisgettingmature.• Moreclinicalstageassetsbeingdevelopedglobally• SeasonedentrepreneurandBDexecutives• Experiencedventurecapitals
üNovelsciencesspringoutfromacademia• Newwaveofstartupsfromacademiaorestablishedcompanies
üBiotechs aregettingvirtualized• Ecosystemisgettingmaturetosupportvirtualbiotechs.
11
CurrentTrends- Virtualization
• SkilledManagement• Seasonedventure
capital• Vendornetwork
(regionalandglobal)• Cutting-edgescience
12
CurrentTrends– Novelscience
• Hanmi- thelastsuccessof“me-tooorme-better”approach?
• Noveltargets• Strongandproprietary
biology
13
CurrentTrends– BDexpertise
• ExperiencedBDexecutive,home-grownandexpats
• Moreoptionsandflexibilitiesindealstructures
14
BridgeBiotherapeutics
• Internalteam:3+• TargetBiology:Pellino-1,validatedbySKKU• Asset:BBT-401(PPI),optimizedbyKRICT• Indication:IBD+• Collaborationnetwork• Universities– KoreanandUK• CRO– Korean,ChinaandUS• Collaborationnetwork
• Clinicaldevelopment:USINDfilingaimedat2H,2017
15
Qurient Therapeutics
• Aspin-offfromInstitut Pasteur Korea
• Semi-virtualoperationwithstrongPMcapability
• OneP2assetinUSAforatopicdermatitis,discoveredbydrugrepurposing
• OneP1assetinUSA,orphandrugdesignatedbyUSFDAforthetreatmentofTB.
• KOSDAQIPOthisyear
16
Oscotec/Genosco
• Genosco (Boston,US)isaspin-offfromOscotec.
KOSDAQ-tradedKoreancorporation.
• EstablishedasUScorporationinBoston
• Semi-virtualoperation
• Twoassets(SYKi andFLT3i)areatP1inUSA
17
ImmunoMet TherapeuticsInc
• Aspin-offfromHanall BioPharma withIND-ready
assetincancermetabolismspace.
• UScorporation,headquarteredinBoston.
• LaboratorieslocatedatJLAB,Houston,Texas.
• SeriesAof$5mcompletedrecently.
18
BiotechA
• Aspin-offfromaprestigiousuniversity.
• UniversityTLOhasminorbutmeaningfulequity
position.
• Novelbiology(GPCRandCNS)withpotential
indicationsforhigh-unmetneedsCNSdiseases
• Scientificfoundervs.managementteam
19
Yuhan Corp.
• Veryactiveinopeninnovationtoovercome
relativelyweakinternalcapability
• ImmuneOncia Therapeutics,LLC,Jointventure
withSorrent Therapeutics,US-basedbiotech
• Regionalrightforthefirstassetandglobalrightfor
thefollowingassets
20
ImplicationstoBD
• Activepre-marketingatvariousinternationalpartneringevents(JPMorgan,BIO,BioEuropeetc)
• IncreasingnumberofbigpharmacompaniesseekingKoreaninnovationsveryactivelyandacoupleofthemtrytogetlocal.
• Koreanpharmacompanies(eg.,Hanmi,DongA,Yuhan,BuKwang andetc.)aresettingupCVCfunctioninternallyorexternally.
21
Koreanbiopharma industry,activeparticipantsinglobalbiophamaindustryasinnovationsources
22
23
JamesJunkue LeeCEO,BridgeBiotherapeutics,Inc.James.Lee@Bridgebiorx.com
Recommended